Lead Sponsor

Vanderbilt University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients on CHD for more than 6 months;
•Ability to read and sign the consent form;
•Have acceptable dialysis adequacy (Kt/V \> 1.2);
•Use biocompatible hemodialysis membrane;
•Have a patent, well functioning, arteriovenous dialysis access or permanent dialysis catheter (no other option for arteriovenous access);
•Signs of chronic inflammation (average CRP of ≥ 5 mg/L for 3 consecutive measurements)

•Pregnancy;
•Intolerance to the study medication;
•Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer, HIV, liver disease);
•Diabetes mellitus on insulin therapy;
•Hospitalization within 1 month prior to the study;
•Malfunctioning arterial-venous vascular access (recirculation and/or blood flow \< 500 ml/min);
•Patients receiving steroids (\> 5 mg/day) and/or other immunosuppressive agents;
•Life-expectancy less than 6 months;
•Age less than 18 years old;
•Atrial fibrillation (only for those undergoing the optional Pulse Wave Velocity);
•Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin (only for those undergoing the optional brachial artery Doppler).

Related studies

NCT06422871 · End Stage Renal Disease, Hemodialysis Access Failure

NCT07157397 · End Stage Renal Disease (ESRD), End Stage Kidney Disease (ESRD), and more

NCT06326905 · Quality of Life, Depression, and more

NCT07020832 · Delayed Graft Function, End Stage Renal Disease, and more

NCT05726526 · Chronic Kidney Disease Stage 5, End Stage Renal Disease

Omega-3 Fatty Acid Administration in Dialysis Patients